piTracer - Automatic reconstruction of molecular cascades for the identification of synergistic drug targets
暂无分享,去创建一个
[1] F. Matsuda,et al. Metabolomics-based phenotypic screens for evaluation of drug synergy via direct-infusion mass spectrometry , 2022, iScience.
[2] I. Enyedy,et al. Discovery of Phospholipase D Inhibitors with Improved Drug-like Properties and Central Nervous System Penetrance. , 2022, ACS medicinal chemistry letters.
[3] Gabor T. Marth,et al. A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology , 2022, Nature Cancer.
[4] D. Hanahan. Hallmarks of Cancer: New Dimensions. , 2022, Cancer discovery.
[5] E. Voest,et al. Tumor organoids: Opportunities and challenges to guide precision medicine. , 2021, Cancer cell.
[6] E. Ruppin,et al. Synthetic lethality-mediated precision oncology via the tumor transcriptome , 2021, Cell.
[7] P. Paoli,et al. Metabolic Reprogramming in Anticancer Drug Resistance: A Focus on Amino Acids. , 2021, Trends in cancer.
[8] Benjamin A. Shoemaker,et al. PubChem in 2021: new data content and improved web interfaces , 2020, Nucleic Acids Res..
[9] Aziz Mithani,et al. MAPPS: A Web-Based Tool for Metabolic Pathway Prediction and Network Analysis in the Postgenomic Era. , 2020, ACS synthetic biology.
[10] James H. Joly,et al. A synthetic lethal drug combination mimics glucose deprivation–induced cancer cell death in the presence of glucose , 2019, The Journal of Biological Chemistry.
[11] A. Ashworth,et al. Synthetic lethality as an engine for cancer drug target discovery , 2019, Nature Reviews Drug Discovery.
[12] D. Wishart. Metabolomics for Investigating Physiological and Pathophysiological Processes. , 2019, Physiological reviews.
[13] Xiaozhuo Chen,et al. Drug resistance and combating drug resistance in cancer , 2019, Cancer drug resistance.
[14] Min Su,et al. The roles of glucose metabolic reprogramming in chemo- and radio-resistance , 2019, Journal of experimental & clinical cancer research : CR.
[15] Fabian J Theis,et al. Dynamic modelling of an ACADS genotype in fatty acid oxidation – Application of cellular models for the analysis of common genetic variants , 2019, PloS one.
[16] A. Silber,et al. Dual inhibition of glutaminase and carnitine palmitoyltransferase decreases growth and migration of glutaminase inhibition–resistant triple-negative breast cancer cells , 2019, The Journal of Biological Chemistry.
[17] Mathias Uhlen,et al. Discovery of therapeutic agents for prostate cancer using genome-scale metabolic modeling and drug repositioning , 2019, EBioMedicine.
[18] Damian Szklarczyk,et al. STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets , 2018, Nucleic Acids Res..
[19] Paul Denny,et al. Genenames.org: the HGNC and VGNC resources in 2019 , 2018, Nucleic Acids Res..
[20] B. Goh,et al. Metabolic reprogramming of oncogene-addicted cancer cells to OXPHOS as a mechanism of drug resistance , 2018, Redox biology.
[21] O. Elemento,et al. Accelerated lipid catabolism and autophagy are cancer survival mechanisms under inhibited glutaminolysis , 2018, bioRxiv.
[22] E. Ruppin,et al. Harnessing synthetic lethality to predict the response to cancer treatment , 2018, Nature Communications.
[23] Piotr Gawron,et al. The Virtual Metabolic Human database: integrating human and gut microbiome metabolism with nutrition and disease , 2018, bioRxiv.
[24] Gary Siuzdak,et al. Metabolomics activity screening for identifying metabolites that modulate phenotype , 2018, Nature Biotechnology.
[25] P. Oefner,et al. Polyol Pathway Links Glucose Metabolism to the Aggressiveness of Cancer Cells. , 2018, Cancer research.
[26] J. Phillip,et al. Metabolomic Profiling Reveals Cellular Reprogramming of B-Cell Lymphoma by a Lysine Deacetylase Inhibitor through the Choline Pathway , 2018, EBioMedicine.
[27] J. Vockley,et al. Inborn Errors of Metabolism with Myopathy: Defects of Fatty Acid Oxidation and the Carnitine Shuttle System. , 2017, Pediatric clinics of North America.
[28] David S. Wishart,et al. HMDB 4.0: the human metabolome database for 2018 , 2017, Nucleic Acids Res..
[29] Daniel C. Zielinski,et al. Recon3D enables a three-dimensional view of gene variation in human metabolism , 2018 .
[30] S. Indraccolo,et al. Linking metabolic reprogramming to therapy resistance in cancer. , 2017, Biochimica et biophysica acta. Reviews on cancer.
[31] Abhijeet R. Sonawane,et al. Understanding Tissue-Specific Gene Regulation , 2017, bioRxiv.
[32] Katharina Anna Zweig,et al. Clustering of Paths in Complex Networks , 2016, COMPLEX NETWORKS.
[33] Julio Saez-Rodriguez,et al. OmniPath: guidelines and gateway for literature-curated signaling pathway resources , 2016, Nature Methods.
[34] Christoph Steinbeck,et al. Reaction Decoder Tool (RDT): extracting features from chemical reactions , 2016, Bioinform..
[35] K. V. van Dijk,et al. Reanalysis of mGWAS results and in vitro validation show that lactate dehydrogenase interacts with branched-chain amino acid metabolism , 2015, European Journal of Human Genetics.
[36] K. Suhre,et al. Metabolic switch during adipogenesis: From branched chain amino acid catabolism to lipid synthesis. , 2016, Archives of biochemistry and biophysics.
[37] G. J. Yoshida. Metabolic reprogramming: the emerging concept and associated therapeutic strategies , 2015, Journal of experimental & clinical cancer research : CR.
[38] A. Vazquez,et al. Pyruvate carboxylation enables growth of SDH-deficient cells by supporting aspartate biosynthesis , 2015, Nature Cell Biology.
[39] G. Kempermann. Faculty Opinions recommendation of Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. , 2015 .
[40] Eytan Ruppin,et al. Predicting Cancer-Specific Vulnerability via Data-Driven Detection of Synthetic Lethality , 2014, Cell.
[41] John P. Overington,et al. An atlas of genetic influences on human blood metabolites , 2014, Nature Genetics.
[42] Mong-Hong Lee,et al. Cancer metabolic reprogramming: importance, main features, and potentials for precise targeted anti-cancer therapies , 2014, Cancer biology & medicine.
[43] P. Johnston,et al. Cancer drug resistance: an evolving paradigm , 2013, Nature Reviews Cancer.
[44] Ming-Huei Chen,et al. A genome-wide association study of the human metabolome in a community-based cohort. , 2013, Cell metabolism.
[45] C. Huttenhower,et al. Passing Messages between Biological Networks to Refine Predicted Interactions , 2013, PloS one.
[46] Ralf Herwig,et al. The ConsensusPathDB interaction database: 2013 update , 2012, Nucleic Acids Res..
[47] E. Ruppin,et al. Predicting selective drug targets in cancer through metabolic networks , 2011, Molecular systems biology.
[48] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[49] R. Wanders,et al. A general introduction to the biochemistry of mitochondrial fatty acid β-oxidation , 2010, Journal of Inherited Metabolic Disease.
[50] Christian Gieger,et al. A genome-wide perspective of genetic variation in human metabolism , 2010, Nature Genetics.
[51] Bin Zhang,et al. Defining clusters from a hierarchical cluster tree: the Dynamic Tree Cut package for R , 2008, Bioinform..
[52] J. Y. Yen,et al. Finding the K Shortest Loopless Paths in a Network , 2007 .
[53] Lei Sun,et al. Crystal structure of the pyridoxal‐5′‐phosphate‐dependent serine dehydratase from human liver , 2005, Protein science : a publication of the Protein Society.
[54] K. Bohren,et al. Characterization of the human aldehyde reductase gene and promoter. , 1999, Genomics.
[55] Hiroyuki Ogata,et al. KEGG: Kyoto Encyclopedia of Genes and Genomes , 1999, Nucleic Acids Res..
[56] S. Yorifuji. [Carnitine/acylcarnitine translocase deficiency]. , 1998, Ryoikibetsu shokogun shirizu.
[57] T. Mosmann. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.